Mirtazapin Hexal (Mirtazapine)

Mirtazapine is indicated for depressive disorders that involve dysregulation of noradrenergic and serotonergic pathways.

• Major depressive disorder: reduces depressive symptoms and improves mood in adult patients.
• Depression with prominent insomnia: helps restore sleep quality while treating mood symptoms.
• Depression with anxiety features: alleviates both depressive and anxiety symptoms in the same therapeutic regimen.

• Mirtazapine acts as an antagonist at central presynaptic α2‑adrenergic receptors, which enhances the release of norepinephrine and serotonin. It also blocks 5‑HT2 and 5‑HT3 receptors and exhibits strong H1‑receptor antagonism, leading to increased noradrenergic and serotonergic neurotransmission while producing sedative effects.

Mirtazapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Sedation or drowsiness
• Increased appetite and weight gain
• Dry mouth
• Constipation
• Dizziness or light‑headedness
• Orthostatic hypotension

Serious or Rare Side Effects

• Agranulocytosis or severe neutropenia
• Life‑threatening hypersensitivity reactions
• Serotonin syndrome when combined with other serotonergic agents
• Suicidal ideation, especially early in treatment
• Hepatic dysfunction or jaundice
• Severe rash or Stevens‑Johnson syndrome

When prescribing or dispensing Mirtazapine, consider the following safety measures.

• Assess hepatic function: adjust use in patients with liver impairment.
• Monitor mood changes: watch for worsening depression or emergence of suicidal thoughts.
• Use caution in cardiovascular disease: may cause orthostatic hypotension.
• Avoid abrupt discontinuation: taper to reduce withdrawal symptoms.
• Evaluate for hypersensitivity: discontinue if severe allergic reaction occurs.
• Store at room temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome.
• Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increase serotonin toxicity.
• Central nervous system depressants (e.g., benzodiazepines, alcohol): enhanced sedation.
• Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): raise mirtazapine plasma levels.
• Alcohol: may intensify sedative effects.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors or inducers: may alter drug concentration.
• Antihypertensive agents: additive blood‑pressure lowering.
• Anticholinergic drugs: increase anticholinergic burden.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened risk of gastrointestinal bleeding.
• Lithium: monitor for neurotoxicity when combined.